HealthDay News — Among pregnant women taking cholecalciferol, factors have been identified that impact serum 25-hydroxyvitamin D (25[OH]D) response, including weight gain and season of delivery, according to research published online October 27 in the Journal of Clinical Endocrinology & Metabolism.
Rebecca J. Moon, BSc, BM, from the University of Southampton in the United Kingdom, and colleagues conducted a within-randomization group analysis of participants in the Maternal Vitamin D Osteoporosis Study. Eight hundred twenty-nine pregnant women were enrolled (422 placebo, 407 cholecalciferol). Maternal anthropometry, health, and lifestyle were assessed at 14 and 34 weeks of gestation and 25(OH)D was measured.
The researchers found that women randomized to vitamin D had higher 25(OH)D at 34 weeks of gestation compared to women randomized to placebo (mean, 67.7 versus 43.1 nmol/L; P<0.001). Among women randomized to cholecalciferol, there were independent associations for lower 25(OH)D at 34 weeks of gestation with higher pregnancy weight gain from 14 to 34 weeks of gestation, lower compliance with study medication, lower early pregnancy 25(OH)D, and delivery in the winter versus the summer.
“Future studies should aim to determine appropriate doses to enable consistent repletion of 25(OH)D during pregnancy,” the authors write
Several authors disclosed financial ties to pharmaceutical and medical device companies, including Merck, which provided the Vigantoletten supplement.